Vermillion is seeking a reverse stock-split in a bid to increase its share price and fend off the threat of being delisted from the Nasdaq exchange.
Late last week, the company formerly known as Ciphergen filed documents with the US Securities and Exchange Commission announcing a special meeting of shareholders to be held on Feb. 14 to vote on the move.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
